Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Brookline Capital Management

Key Points

• Y-mAbs Therapeutics has been downgraded by Brookline Capital Management from a "strong-buy" to a "hold" rating, reflecting a shift in analyst sentiment.
• Multiple firms have set target prices for Y-mAbs stock, ranging from $3.00 by Bank of America to $8.60 by both Cantor Fitzgerald and Morgan Stanley, indicating a cautious outlook for the company.
• The stock has experienced significant fluctuations, with a 52-week low of $3.55 and a high of $16.11, and currently holds an average analysts' rating of "hold" with a target price of $11.16.

Brookline Capital Management cut shares of Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) from a strong-buy rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the stock. Oppenheimer downgraded shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday, August 5th. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their target price for the company from $26.00 to $8.60 in a research note on Tuesday, August 5th. HC Wainwright restated a "neutral" rating and issued a $8.60 target price (down previously from $11.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday, August 6th. Wedbush downgraded shares of Y-mAbs Therapeutics from an "outperform" rating to a "neutral" rating and set a $8.60 target price on the stock. in a research note on Tuesday, August 5th. Finally, Truist Financial set a $8.60 target price on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of "Hold" and a consensus price target of $11.16.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock traded up $0.01 during midday trading on Tuesday, hitting $8.52. The company had a trading volume of 636,937 shares, compared to its average volume of 476,145. The business's 50 day simple moving average is $4.94 and its two-hundred day simple moving average is $4.93. The stock has a market cap of $385.56 million, a PE ratio of -17.03 and a beta of 0.57. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.34%. The firm had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. On average, sell-side analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in shares of Y-mAbs Therapeutics by 59.5% during the 4th quarter. Bank of America Corp DE now owns 127,159 shares of the company's stock worth $996,000 after acquiring an additional 47,439 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Y-mAbs Therapeutics by 107.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock worth $119,000 after acquiring an additional 13,890 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after acquiring an additional 6,131 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Y-mAbs Therapeutics by 17.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock worth $410,000 after acquiring an additional 7,765 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after acquiring an additional 8,820 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.